Trials / Completed
CompletedNCT02221882
A Study of LY3164530 in Participants With Cancer
A Phase 1 Study of LY3164530, a Bispecific Antibody Targeting Mesenchymal-Epithelial Transition Factor (MET) and Epidermal Growth Factor Receptor (EGFR), in Patients With Advanced or Metastatic Cancer
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 29 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to evaluate the safety of a study drug known as LY3164530 in participants with cancer that is advanced and/or has spread to another part(s) of the body.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | LY3164530 | Administered IV. |
Timeline
- Start date
- 2014-08-01
- Primary completion
- 2017-03-07
- Completion
- 2017-03-07
- First posted
- 2014-08-21
- Last updated
- 2019-10-23
- Results posted
- 2019-10-23
Locations
3 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT02221882. Inclusion in this directory is not an endorsement.